449 related articles for article (PubMed ID: 32084574)
1. Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation.
Alshweiat A; Csóka I; Tömösi F; Janáky T; Kovács A; Gáspár R; Sztojkov-Ivanov A; Ducza E; Márki Á; Szabó-Révész P; Ambrus R
Int J Pharm; 2020 Apr; 579():119166. PubMed ID: 32084574
[TBL] [Abstract][Full Text] [Related]
2. Design and characterization of loratadine nanosuspension prepared by ultrasonic-assisted precipitation.
Alshweiat A; Katona G; Csóka I; Ambrus R
Eur J Pharm Sci; 2018 Sep; 122():94-104. PubMed ID: 29908301
[TBL] [Abstract][Full Text] [Related]
3. Fabrication of surfactant-stabilized nanosuspension of naringenin to surpass its poor physiochemical properties and low oral bioavailability.
Singh MK; Pooja D; Ravuri HG; Gunukula A; Kulhari H; Sistla R
Phytomedicine; 2018 Feb; 40():48-54. PubMed ID: 29496174
[TBL] [Abstract][Full Text] [Related]
4. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
5. Formulation and evaluation of mucoadhesive buccal films impregnated with carvedilol nanosuspension: a potential approach for delivery of drugs having high first-pass metabolism.
Rana P; Murthy RS
Drug Deliv; 2013; 20(5):224-35. PubMed ID: 23651066
[TBL] [Abstract][Full Text] [Related]
6. A simple and low-energy method to prepare loratadine nanosuspensions for oral bioavailability improvement: preparation, characterization, and in vivo evaluation.
Yang D; Li R; Zhang F; Qin L; Peng F; Jiang S; He H; Lu X; Zhang P
Drug Deliv Transl Res; 2020 Feb; 10(1):192-201. PubMed ID: 31482518
[TBL] [Abstract][Full Text] [Related]
7. Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement.
Zawar LR; Bari SB
Recent Pat Drug Deliv Formul; 2018; 12(3):162-169. PubMed ID: 30003863
[TBL] [Abstract][Full Text] [Related]
8. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
Nagaraj K; Narendar D; Kishan V
Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
[TBL] [Abstract][Full Text] [Related]
9. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.
Zhang X; Zhang T; Lan Y; Wu B; Shi Z
AAPS PharmSciTech; 2016 Apr; 17(2):400-8. PubMed ID: 26187778
[TBL] [Abstract][Full Text] [Related]
10. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
Jain S; Reddy VA; Arora S; Patel K
Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
[TBL] [Abstract][Full Text] [Related]
11. Intranasal Zotepine Nanosuspension: intended for improved brain distribution in rats.
Pailla SR; Talluri S; Rangaraj N; Ramavath R; Challa VS; Doijad N; Sampathi S
Daru; 2019 Dec; 27(2):541-556. PubMed ID: 31256410
[TBL] [Abstract][Full Text] [Related]
12. Preparation of loratadine nanocrystal tablets to improve the solubility and dissolution for enhanced oral bioavailability.
Li J; Zhou Y; Aisha M; Wu J; Wang H; Huang F; Sun M
J Pharm Pharmacol; 2021 Jun; 73(7):937-946. PubMed ID: 33963858
[TBL] [Abstract][Full Text] [Related]
13. Chitosan-coated diacerein nanosuspensions as a platform for enhancing bioavailability and lowering side effects: preparation, characterization, and ex vivo/in vivo evaluation.
Allam AN; Hamdallah SI; Abdallah OY
Int J Nanomedicine; 2017; 12():4733-4745. PubMed ID: 28740381
[TBL] [Abstract][Full Text] [Related]
14. Nose-to-Brain Delivery by Nanosuspensions-Based in situ Gel for Breviscapine.
Chen Y; Liu Y; Xie J; Zheng Q; Yue P; Chen L; Hu P; Yang M
Int J Nanomedicine; 2020; 15():10435-10451. PubMed ID: 33380794
[TBL] [Abstract][Full Text] [Related]
15. Novel self-nanoemulsifying self-nanosuspension (SNESNS) for enhancing oral bioavailability of diacerein: Simultaneous portal blood absorption and lymphatic delivery.
El-Laithy HM; Basalious EB; El-Hoseiny BM; Adel MM
Int J Pharm; 2015 Jul; 490(1-2):146-54. PubMed ID: 26002566
[TBL] [Abstract][Full Text] [Related]
16. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
Patel PJ; Gajera BY; Dave RH
Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
Kassem MAA; ElMeshad AN; Fares AR
AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
[TBL] [Abstract][Full Text] [Related]
18. Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition.
Rahim H; Sadiq A; Khan S; Amin F; Ullah R; Shahat AA; Mahmood HM
Int J Nanomedicine; 2019; 14():6287-6296. PubMed ID: 31496686
[TBL] [Abstract][Full Text] [Related]
19. Enhanced bioavailability of cinnarizine nanosuspensions by particle size engineering: Optimization and physicochemical investigations.
Mishra B; Sahoo J; Dixit PK
Mater Sci Eng C Mater Biol Appl; 2016 Jun; 63():62-9. PubMed ID: 27040196
[TBL] [Abstract][Full Text] [Related]
20. Preparation, characterization and pharmacokinetics of cyadox nanosuspension.
Sattar A; Chen D; Jiang L; Pan Y; Tao Y; Huang L; Liu Z; Xie S; Yuan Z
Sci Rep; 2017 May; 7(1):2289. PubMed ID: 28536446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
